Apricus Biosciences in brief
Apricus Biosciences is an unlisted company in the Biotechnology industry, based in San Diego, USA. It was founded in 1987. In the year to December 2023 it had sales of $2 M and a net loss of $38 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Apricus Biosciences
Apricus Biosciences, Inc. is a San Diego–based biopharmaceutical company advancing innovative medicines in urology and rheumatology.
Apricus Biosciences' first product, Vitaros®, has been approved in Europe and Canada for the treatment of erectile dysfunction Other compounds in development include: low testosterone, rheumatology, sexual dysfunction, pain,
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Apricus Biosciences timeline
- 1987
- 🏁· approximateFounded
- 1997
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed Apricus Biosciences, Inc.Formerly Nexmed Inc.
- 🔔· approximateInitial public offering on Nasdaq as APRI
- 2019
- ✎Renamed Seelos Therapeutics, Inc.Formerly Apricus Biosciences, Inc..
Events of Apricus Biosciences from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Apricus Biosciences
- Acquisitions and changes
- Delisted: the exchange removed its shares from listing (Form 25-NSE) on 4 April 2025.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -1721.8%
- Operating margin
- -1840.9%
- Return on equity
- —
- Liabilities / assets
- 718.3%
- Net debt
- $11M
- Revenue growth
- +478.9%
- R&D / revenue
- 1369.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2023 | $2M | — | $-41M | $-38M | -1721.8% |
| Dec 2022 | — | — | $-71M | $-74M | — |
| Dec 2021 | — | — | $-62M | $-66M | — |
| Dec 2020 | — | — | $-19M | $-19M | — |
| Dec 2019 | $0M | — | $-30M | $-51M | -13489.5% |
| Dec 2018 | — | — | $-3M | $-3M | — |
| Dec 2017 | — | — | $-11M | $0M | — |
| Dec 2016 | $6M | — | $-14M | $-7M | -129.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2023 | $-24M | — | — | $-7.73 | — |
| Dec 2022 | $-62M | — | — | $-20.74 | — |
| Dec 2021 | $-49M | — | — | $-0.73 | — |
| Dec 2020 | $-21M | — | — | $-0.43 | — |
| Dec 2019 | $-19M | — | — | $-2.52 | — |
| Dec 2018 | $-2M | — | — | $-1.13 | — |
| Dec 2017 | $-11M | $0M | $-11M | $0.81 | — |
| Dec 2016 | $-13M | $0M | $-13M | $-1.15 | — |
Quarterly results
Latest quarter to Jun 2024: revenue $0M (+11.8% on a year earlier), net income $2M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 22, 20248-KCurrent reportBankruptcy · Other events
- Oct 24, 20248-KCurrent reportShareholder vote · Other events
- Oct 15, 20248-KCurrent reportListing notice · Other events
- Oct 7, 20248-KCurrent reportOther events
- Sep 26, 20248-KCurrent reportShareholder vote · Other events
- Sep 25, 20248-KCurrent reportBylaws amended · Regulation FD disclosure
- Sep 25, 2024S-1IPO registration
- Sep 24, 20248-KCurrent reportOther events
- Sep 3, 20248-KCurrent reportMaterial agreement
- Aug 20, 2024DEF 14AProxy statement
- Aug 14, 202410-QQuarterly report · period to Jun 2024
- Aug 8, 20248-KCurrent report
Official filings of Apricus Biosciences with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-41 M
- Net income
- $-38 M
For year ending December-2023 · source: SEC filing
Balance sheet
- Total assets
- $5 M
- Total liabilities
- $39 M
- Total equity
- $-34 M
As of December-2023
Insider trading at Apricus Biosciences#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Michael Joseph GolembiewskiChief Financial Officer | Grant or award | +417 | $1.100 | $459 | 86,869 | Form 4 |
| filed | Raj MehraSee Remarks, Director | Buy | +75,757 | $1.320 | $100 K | 185,142 | Form 4 |
| filed | Michael Joseph GolembiewskiChief Financial Officer | Buy | +83,000 | $1.210 | $100 K | 86,450 | Form 4 |
| filed | Michael Joseph GolembiewskiChief Financial Officer | Grant or award | +12,500 | $0.620 | $8 K | 103,487 | Form 4 |
| filed | Michael Joseph GolembiewskiChief Financial Officer | Grant or award | +12,500 | $0.670 | $8 K | 90,987 | Form 4 |
| filed | Daniel J. O'ConnorDirector | Buy | +16,000 | $0.610 | $10 K | 16,000 | Form 4 |
| filed | Margaret DalesandroDirector | Buy | +35,000 | $0.600 | $21 K | 35,000 | Form 4 |
| filed | Raj MehraSee Remarks, Director | Buy | +66,667 | $0.850 | $57 K | 3.28 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Apricus Biosciences#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-33.33 reverse split ; 1-for-10 reverse split
Bankruptcy filing: (8-K)
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $1.2M |
| Q4 2015 | Q4 2015 | $0M |
| Q3 2015 | Q3 2015 | $0M |
| Q4 2014 | Q4 2014 | $0M |
| Q3 2014 | Q3 2014 | $0M |
| Q4 2013 | Q4 2014 | $0M |
| Q3 2013 | Q3 2014 | $0M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Apricus Biosciences scorecard#
Passes 0 of the 8 checks that could be worked out. Fiscal year 2023.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-7.73 vs -20.74Diluted EPS -7.73 in fiscal 2023 against -20.74 the year before (report's currency).
- ✗Net income higher than five years earlier-$38 M-$38 M in fiscal 2023 against -$3 M in 2018.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$38 MNet income -$38 M in fiscal 2023.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.14 at the end of fiscal 2023.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-506.2×Operating income -506.2 times interest in fiscal 2023.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year38.2%Diluted shares up 38.2% in fiscal 2023.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Apricus Biosciences: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 2.2—100% | — | — | 0−100%— | 0.4—100% | 0−100%— | 0.5−91.1%100% | 5.8+19.1%100% | 4.8−47.7%100% | 9.3—100% | |
| Cost of revenue | — | — | — | — | — | — | — | 0.5−44.6%8.9% | 0.9+0.4%19.1% | 0.9—9.9% | |
| Gross profit | — | — | — | — | — | — | — | 1.9−52.2%32.5% | 3.9−53.0%80.9% | 8.3—90.1% | |
| Research and development | 30−48.6%1367% | 59+25.7%— | 47+325%— | 11−51.3%— | 23+3980%6017% | 0.6r1.2−84.0%— | 3.5−41.1%678% | 5.9r6.8−59.9%102% | 15−31.2%303% | 21—230% | |
| General and administrative | 13+2.4%571% | 12−18.1%— | 15+93.2%— | 7.8+2.9%— | 7.6+187%2016% | 2.6r7.9−63.5%— | 7.2−7.3%1411% | 7.8r8.4−26.0%135% | 11−7.9%217% | 11—123% | |
| Operating expenses | 43−39.8%1938% | 71+15.0%— | 62+229%— | 19−37.7%— | 30+846%8033% | 3.2r9.1−70.2%— | 11−21.9%2089% | 14r15−45.9%237% | 25−18.2%522% | 31—334% | |
| Operating income | −40—−1838% | −71—— | −62—— | −19—— | −30—−7933% | −3.2r−9.1—— | −11—−2089% | −14r−13—−237% | −21—−441% | −23—−244% | |
| Interest expense and finance costs | 0.1+436%3.4% | 0.0−99.1%— | 1.6+874%— | 0.2+466%— | 0.0−77.9%7.7% | 0.1+31.0%— | 0.1−90.0%19.6% | 1.0+25.0%17.4% | 0.8+700%16.5% | 0.1—1.1% | |
| Other non-operating income (expense) | 2.6—119% | −2.6—— | −4.4—— | −0.3—— | −22—−5735% | −0.3r−0.1—— | −1.1−118%−210% | 6.0r6.0+158%104% | 2.3+2738%48.1% | 0.1—0.9% | |
| Income tax | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | |
| Income from continuing operations | — | — | — | — | — | −9.2—— | −12—−2299% | −7.7—−133% | −19—−393% | −22—−243% | |
| Income from discontinued operations | — | — | — | — | — | −0.0−100%— | 12+5241%2362% | 0.2—3.9% | 0−100%0.0% | 0.7—7.5% | |
| Net income attributable to shareholders | −38—−1720% | −74—— | −66—— | −19—— | −51—−13668% | −3.5r−9.2−1183%— | 0.3—62.8% | −7.4—−129% | −19—−393% | −22—−235% | |
| Earnings per share, basic | -7.73—— | -20.74r-0.69—— | -0.73—— | -0.43—— | -2.52—— | -1.13r-12.14−240%— | 0.81r0.02—— | -1.15r-1.14—— | -3.83r-0.38—— | -0.55—— | |
| Earnings per share, diluted | -7.73—— | -20.74r-0.69—— | -0.73—— | -0.43—— | -2.52—— | -1.13r-12.14−240%— | 0.81r0.02—— | -1.15r-1.14—— | -3.83r-0.38—— | -0.55—— | |
| Shares, weighted average (basic) | 4.9+38.2%— | 3.5r106−96.1%— | 91—— | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 4.9+38.2%— | 3.5r106−96.1%— | 91+103%— | 45+120%— | 20+559%— | 3.1r0.8+678%— | 0.4r12−93.9%— | 6.5r6.5+31.1%— | 5.0r50−87.4%— | 40—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.0−80.7%55.3% | 16−80.3%68.3% | 79+403%94.3% | 16+52.6%89.5% | 10+24331%92.5% | 0.0r3.6−83.7%22.0% | 0.3r6.3−87.6%3.8% | 2.1−46.3%44.4% | 3.9−65.9%50.0% | 11—77.0% | |
| Receivables | 0.8—14.1% | — | — | — | — | — | — | 0.5+2.1%11.3% | 0.5−23.5%6.7% | 0.7—4.6% | |
| Inventory | — | — | — | — | — | — | — | 0.8+62.9%16.3% | 0.5+70.5%6.0% | 0.3—1.9% | |
| Other current assets | 1.6−77.0%30.3% | 7.1+51.1%31.4% | 4.7+158%5.7% | 1.8+119%10.5% | 0.8+9178%7.5% | 0.0r0.1−96.6%4.7% | 0.3+47.5%3.9% | 0.2r0.3−83.3%3.8% | 1.1r1.1+64.4%13.6% | 0.6—4.4% | |
| Current assets | 5.4−76.2%99.7% | 23−72.8%99.7% | 83+377%100.0% | 17+57.7%100% | 11+5709%100% | 0.2r3.7−97.1%100% | 6.6+81.4%98.3% | 3.6−41.5%77.3% | 6.2r6.3−53.2%79.9% | 13—89.7% | |
| Property, plant and equipment | — | — | — | — | — | 0.0−51.9%19.9% | 0.1−51.8%1.2% | 0.2r1.0−87.3%3.5% | 1.3−5.0%16.6% | 1.4—9.2% | |
| Right-of-use (leased) assets | 0.0−79.2%0.3% | 0.1+84.6%0.3% | 0.0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Total assets | 5.4−76.2%100% | 23−72.8%100% | 84+377%100% | 17+57.7%100% | 11+5709%100% | 0.2r3.8−97.2%100% | 6.7+42.7%100% | 4.7−39.6%100% | 7.8r7.9−47.5%100% | 15—100% | |
| Accounts payable | 16+352%303% | 3.6+114%15.9% | 1.7−10.3%2.0% | 1.9+137%10.8% | 0.8−64.1%7.2% | 2.2r0.2+3728%1162% | 0.1−92.4%0.9% | 0.8r1.0−51.7%16.2% | 1.6+83.7%20.3% | 0.9—5.8% | |
| Current liabilities | 39+54.7%718% | 25+204%111% | 8.3+11.5%9.9% | 7.4−31.1%42.5% | 11+120%97.1% | 4.9r1.2+209%2564% | 1.6−86.0%23.6% | 11−28.0%240% | 16r16+127%202% | 6.9—46.6% | |
| Lease liabilities (non-current) | — | 0.0—0.1% | — | 0—0.0% | — | — | — | — | — | — | |
| Total liabilities | 39+16.7%718% | 33+27.4%147% | 26+75.4%31.3% | 15+34.4%85.3% | 11+127%100% | 4.9r1.2+110%2564% | 2.3−80.9%34.8% | 12−31.1%260% | 18r18+37.5%228% | 13—87.0% | |
| Retained earnings | −253—−4663% | −215—−944% | −141r141−288%−169% | 75r−75—430% | −56—−505% | −4.8r−325—−2516% | −316—−4712% | −316—−6730% | −309—−3970% | −290—−1957% | |
| Shareholders' equity | −34—−618% | −11−119%−46.6% | 57+2129%68.7% | 2.6—14.7% | −0.0—−0.1% | −4.7r2.6—−2464% | −1.3r4.4—−18.8% | −7.5—−160% | −9.9−618%−128% | 1.9—13.0% | |
| Total liabilities and equity | 5.4−76.2%100% | 23−72.8%100% | 84+377%100% | 17+57.7%100% | 11+5709%100% | 0.2r3.8−97.2%100% | 6.7+42.7%100% | 4.7−39.6%100% | 7.8r7.9−47.5%100% | 15—100% | |
| Shares outstanding | 1.2r9.8−65.7%— | 3.6r107−96.6%— | 106+93.5%— | 55+102%— | 27+777%— | 3.1r0.9+508%— | 0.5r15−93.4%— | 7.7+53.4%— | 5.0r50−88.6%— | 44—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | 0.0−65.0%— | 0.1+10.4%22.9% | 0.1r0.3−64.7%1.8% | 0.3+76.5%6.2% | 0.2—1.8% | |
| Share-based compensation | 4.0−21.4%181% | 5.1−39.2%— | 8.3+308%— | 2.0+345%— | 0.5+1291%122% | 0.0r1.3−97.1%— | 1.1−34.9%223% | 1.7+44.4%30.3% | 1.2−30.1%25.0% | 1.7—18.7% | |
| Cash from operating activities | −24—−1085% | −62—— | −49—— | −21—— | −19—−5148% | −1.6r−8.1—— | −11—−2069% | −13—−227% | −23—−468% | −18—−195% | |
| Capital expenditure | — | — | — | — | — | — | 0—0.0% | −0.0—−0.3% | −0.3—−7.0% | −0.6—−6.3% | |
| Cash from investing activities | — | — | — | — | — | — | 0−100%0.0% | 0.3—4.6% | −0.3r−0.3—−6.7% | −0.5—−5.7% | |
| Debt repaid | — | — | — | — | — | — | −6.6—−1292% | — | — | — | |
| Shares issued | — | — | 98+1007%— | 8.9r0−46.4%— | 17—4405% | 0r4.8−100%— | 11−27.3%2100% | 15r14+35.8%256% | 11+83.8%225% | 5.9—63.9% | |
| Shares bought back | −1.2—−54.2% | — | — | — | — | — | — | — | 0—0.0% | −0.0—−0.5% | |
| Cash from financing activities | 11—516% | −1.6−101%— | 112+326%— | 26−10.9%— | 30+2063%7873% | 1.4r5.4−45.4%— | 2.5−77.3%489% | 11−28.8%191% | 15r15+96.5%319% | 7.9—84.9% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Change in cash | −13—−569% | −63−200%— | 63+1068%— | 5.4−47.1%— | 10—2725% | −0.2r−2.8−105%— | 4.2—831% | −1.8—−31.2% | −7.5—−155% | −10—−108% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 | Q4 FY2021to Dec 31, 2021 | Q3 FY2021to Sep 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 2.0—100% | 0.4+11.9%100% | 0.6−28.3%100% | 0.7*—100% | 0.4—100% | 0.3—100% | 0.8—100% | — | — | — | — | — | — | |
| Research and development | 20−54.0%1014% | 1.0−88.6%257% | 3.5−37.8%609% | 5.9*−61.8%906% | 10−32.1%2468% | 8.5−53.6%2532% | 5.7−43.4%701% | 16*−20.7%— | 15+69.9%— | 18—— | 10—— | 20*—— | 8.7—— | |
| General and administrative | 11−7.1%566% | 2.5−8.3%678% | 3.1−23.6%537% | 2.7*−0.2%421% | 3.0+12.3%736% | 2.8−3.6%827% | 4.1+1.8%504% | 2.8*−64.8%— | 2.7+19.4%— | 2.9—— | 4.0—— | 7.8*—— | 2.2—— | |
| Operating expenses | 32−43.9%1580% | 3.5−68.9%935% | 6.6−31.9%1146% | 8.7*−52.5%1327% | 13−25.3%3204% | 11−46.8%3360% | 9.7−30.5%1205% | 18*−33.3%— | 17+59.6%— | 21—— | 14—— | 27*—— | 11—— | |
| Operating income | −30—−1480% | −3.1—−835% | −6.1—−1046% | −8.0*—−1227% | −13—−3104% | −11—−3260% | −8.9—−1105% | −18*—— | −17—— | −21—— | −14—— | −27*—— | −11—— | |
| Interest expense and finance costs | 0.1+569%5.3% | 0.0+229%6.1% | 0.0+229%4.0% | 0.0*—2.9% | 0.0+2000%10.3% | 0.0+40.0%2.1% | 0.00.0%0.9% | 0*−100%— | 0.0−90.0%— | 0.0—— | 0.0—— | 0.0*—— | 0.0—— | |
| Other non-operating income (expense) | 34—1683% | 4.8—1290% | 3.4—586% | 2.6*—392% | 23—5690% | −19—−5519% | −4.5−50089%−557% | −0.4*−448%— | −2.2−2409%— | −0.0—— | 0.0—— | 0.1*—— | 0.1—— | |
| Net income attributable to shareholders | 4.1—203% | 1.7—455% | −2.7—−460% | −5.5*—−835% | 10—2586% | −29r−29—−8779% | −13—−1662% | −19*—— | −20—— | −21—— | −14—— | −27*—— | −11—— | |
| Earnings per share, basic | — | 0.68—— | -0.20—— | — | 0.08—— | -53.66r-0.22—— | -3.58r-0.12—— | — | -0.18—— | -0.20—— | -0.13—— | — | -0.11—— | |
| Earnings per share, diluted | — | 0.12—— | -0.20—— | — | -0.12—— | -53.66r-0.22—— | -3.58r-0.12—— | — | -0.18—— | -0.20—— | -0.13—— | — | -0.11—— | |
| Shares, weighted average (basic) | 2.5+356%— | 2.5+356%— | 13+247%— | — | 135+26.8%— | 0.5r132−99.5%— | 3.8r113−96.4%— | — | 107+4.3%— | 106—— | 106—— | — | 102—— | |
| Shares, weighted average (diluted) | 2.5+358%— | 2.5+358%— | 13+247%— | — | 148+38.8%— | 0.5r132−99.5%— | 3.8r113−96.4%— | — | 107+4.3%— | 106—— | 106—— | — | 102—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.3—12.3% | 0.3−95.0%12.3% | 0.5−96.3%14.5% | 3.0−80.7%55.3% | 2.6−91.5%41.6% | 5.8−85.8%49.1% | 14−77.2%59.5% | 16−80.3%68.3% | 31−60.3%75.3% | 41—78.3% | 62—87.4% | 79—94.3% | 77—94.9% | |
| Receivables | 0.2—7.9% | 0.2−56.4%7.9% | 1.0+22.1%26.8% | 0.8—14.1% | 0.2—3.6% | 0.4—3.6% | 0.8—3.4% | — | — | — | — | — | — | |
| Other current assets | 1.9—77.8% | 1.9−66.8%77.8% | 2.1−76.4%57.0% | 1.6−77.0%30.3% | 3.4−66.2%54.4% | 5.6−51.1%46.9% | 8.7−1.8%36.9% | 7.1+51.1%31.4% | 10.0+146%24.7% | 11—21.7% | 8.9—12.6% | 4.7—5.7% | 4.1—5.0% | |
| Current assets | 2.3—98.0% | 2.3−80.3%98.0% | 3.6−84.9%98.3% | 5.4−76.2%99.7% | 6.2−84.7%99.5% | 12−77.5%99.6% | 24−66.6%99.8% | 23−72.8%99.7% | 41−49.9%100% | 53—100.0% | 71—100.0% | 83—100.0% | 81—99.9% | |
| Right-of-use (leased) assets | 0.0—2.0% | 0.0+6.8%2.0% | 0.1+6.9%1.7% | 0.0−79.2%0.3% | 0.0—0.5% | 0.0+238%0.4% | 0.1+123%0.2% | 0.1+84.6%0.3% | — | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.1—0.1% | |
| Total assets | 2.4—100% | 2.4−80.0%100% | 3.6−84.7%100% | 5.4−76.2%100% | 6.2−84.6%100% | 12−77.4%100% | 24−66.6%100% | 23−72.8%100% | 41−50.0%100% | 53—100% | 71—100% | 84—100% | 81—100% | |
| Accounts payable | 16—659% | 16+144%659% | 15+156%423% | 16+352%303% | 9.3+56.6%150% | 6.4+179%54.1% | 6.0+180%25.2% | 3.6+114%15.9% | 6.0+75.0%14.7% | 2.3—4.4% | 2.1—3.0% | 1.7—2.0% | 3.4—4.2% | |
| Current liabilities | 31—1282% | 31−45.6%1282% | 37−6.3%1017% | 39+54.7%718% | 35+61.4%568% | 56+284%472% | 39+287%166% | 25+204%111% | 22+172%54.0% | 15—27.8% | 10—14.3% | 8.3—9.9% | 8.0—9.9% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | 0.0—0.1% | — | — | — | — | — | |
| Total liabilities | 31—1282% | 31−48.3%1282% | 37−17.1%1017% | 39+16.7%718% | 37+12.3%589% | 59+123%497% | 44+76.8%187% | 33+27.4%147% | 33+306%80.5% | 26—50.2% | 25—35.4% | 26—31.3% | 8.0—9.9% | |
| Retained earnings | −254—−10650% | −254—−10650% | −255—−7068% | −253—−4663% | −247−226%−3975% | −258−246%−2167% | −228−247%−965% | −215—−944% | 196—484% | 176—335% | 155—220% | −141r141—−169% | −114—−141% | |
| Shareholders' equity | −28—−1182% | −28—−1182% | −33—−917% | −34—−618% | −30−486%−489% | −47−280%−397% | −21−145%−87.4% | −11−119%−46.6% | 7.9−89.2%19.5% | 26—49.8% | 46—64.6% | 57—68.7% | 73—90.1% | |
| Total liabilities and equity | 2.4—100% | 2.4−80.0%100% | 3.6−84.7%100% | 5.4−76.2%100% | 6.2−84.6%100% | 12−77.4%100% | 24−66.6%100% | 23−72.8%100% | 41−50.0%100% | 53—100% | 71—100% | 84—100% | 81—100% | |
| Shares outstanding | 3.3—— | 3.3−97.3%— | 15−87.5%— | 1.2r9.8−65.7%— | 160+48.8%— | 124+16.9%— | 122+15.4%— | 3.6r107−96.6%— | 107+4.7%— | 106—— | 106—— | 106—— | 102—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 3.8−4.2%187% | 0.9−11.7%232% | 1.0−10.1%165% | 1.0*+6.3%148% | 1.0+0.1%240% | 1.0+2.8%294% | 1.1−52.4%131% | 0.9*−84.2%— | 1.0+13.5%— | 1.0—— | 2.2—— | 5.7*—— | 0.9—— | |
| Cash from operating activities | −13—−659% | −1.0*—−259% | −4.6—−802% | −1.9*—−293% | −5.7*—−1416% | −5.9*—−1757% | −10—−1281% | −13*—— | −11*—— | −20*—— | −17—— | −18*—— | −11*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | |
| Shares bought back | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −1.2—−148% | — | — | — | — | — | — | |
| Cash from financing activities | 7.7+54.3%384% | 0.7*—197% | 2.2−75.5%375% | 2.3*—356% | 2.5*+646%613% | −2.3*—−688% | 8.9+10592%1098% | −1.9*−109%— | 0.3*+134%— | −0.1*—— | 0.1—— | 20*—— | 0.1*—— | |
| Change in cash | −5.5—−276% | −0.2*—−61.2% | −2.5—−427% | 0.4*—63.1% | −3.3*—−803% | −8.2*—−2445% | −1.5—−182% | −15*−888%— | −11*—— | −21*—— | −17—— | 1.9*—— | −10*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Apricus Biosciences#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Bankruptcy or receivership 1 · Delisting notice 3 · Restructuring 1 · Directors and officers 1 · Material agreement 11 · Agreement ended 1 · Unregistered share sale 4 · Shareholder rights changed 4 · Bylaws or fiscal year changed 4 · Shareholder vote 3
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivership | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting noticeRestructuringDirectors and officersMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 22, 2024
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2016 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2012 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 33% of workforce | Restructuring planSEC 8-K | “On April 30, 2024, the Company announced a reduction in its workforce that affected approximately 33% of its current employees (the “RIF”), along with a reduction in working hours …” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Apricus Biosciences compares in Biotechnology
- Revenue$2 M · higher than 31% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Apricus Biosciences🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2023
- Balance sheet:
- As of December-2023
- Profile updated:
- Nov 14, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Apricus Biosciences? Verify and update this profile — free
Show Apricus Biosciences's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.